Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 2, 2011, Pages 359-374

  Stravopodis, Dimitrios J ^a   Karkoulis, Panagiotis K ^b   Konstantakou, Eumorphia G ^a   Melachroinou, Sophia ^b   Thanasopoulou, Angeliki ^c   Aravantinos, Gerasimos ^d   Margaritis, Lukas H ^a   Anastasiadou, Ema ^c   Voutsinas, Gerassimos E ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d General Oncology Hospital Agioi Anargyroi   (Greece)

Author keywords

5 Fluorouracil; Apoptosis; Bladder cancer; E2F; p53; Thymidylate synthase

Indexed keywords

FLUOROURACIL; PROTEIN P53; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GRADING; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASES; E2F1 TRANSCRIPTION FACTOR; ENZYME INHIBITORS; FLUOROURACIL; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 78751611206     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0891-y     Document Type: Article

References (59)

1. BL Adamsen KL Kravik OP Clausen PM De Angelis 2007 Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment Int J Oncol 31 1491 1500 1:CAS:528:DC%2BD2sXhsVKgur%2FO 17982676
2. DJ Ahnen P Feigl G Quan C Fenoglio-Preiser LC Lovato PA Bunn Jr G Stemmerman JD Wells JS Macdonald FL Meyskens Jr 1998 Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study Cancer Res 58 1149 1158 1:CAS:528:DyaK1cXhvV2rsro%3D 9515799
3. T Ando H Ishiguro Y Kuwabara M Kimura A Mitsui N Sugito R Mori R Ogawa T Katada Y Fujii 2008 Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines Dis Esophagus 21 15 20 1:STN:280:DC%2BD1c%2FksVentg%3D%3D 18197934
4. SP Angus LJ Wheeler SA Ranmal X Zhang MP Markey CK Mathews ES Knudsen 2002 Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication J Biol Chem 277 44376 44384 1:CAS:528:DC%2BD38Xos1aktLY%3D 10.1074/jbc.M205911200 12221087 (Pubitemid 36157873)
5. C Backes J Kuentzer HP Lenhof N Comtesse E Meese 2005 GraBCas: a bioinformatics tool for score-based prediction of caspase- and granzyme B-cleavage sites in protein sequences Nucleic Acids Res 33 W208 W213 1:CAS:528:DC%2BD2MXlslyqsLg%3D 10.1093/nar/gki433 15980455 (Pubitemid 44529910)
6. HH Backus D Wouters CG Ferreira VM van Houten RH Brakenhoff HM Pinedo GJ Peters 2003 Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines Eur J Cancer 39 1310 1317 1:CAS:528:DC%2BD3sXjvFelu74%3D 10.1016/S0959-8049(03)00204-1 12763222 (Pubitemid 36579205)
7. SH Berger DL Pittman MD Wyatt 2008 Uracil in DNA: consequences for carcinogenesis and chemotherapy Biochem Pharmacol 76 697 706 1:CAS:528:DC%2BD1cXhtVyku7nF 10.1016/j.bcp.2008.05.019 18599024
8. PM Borralho IB Moreira da Silva MM Aranha C Albuquerque C Nobre Leitao CJ Steer CM Rodrigues 2007 Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53 Biochim Biophys Acta 1772 40 47 1:CAS:528:DC%2BD2sXht1SqsQ%3D%3D 17056233
9. J Boyer EG McLean S Aroori P Wilson A McCulla PD Carey DB Longley PG Johnston 2004 Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan Clin Cancer Res 10 2158 2167 1:CAS:528:DC%2BD2cXisVGks7o%3D 10.1158/1078-0432.CCR-03- 0362 15041737 (Pubitemid 38375578)
10. F Bunz PM Hwang C Torrance T Waldman Y Zhang L Dillehay J Williams C Lengauer KW Kinzler B Vogelstein 1999 Disruption of p53 in human cancer cells alters the responses to therapeutic agents J Clin Invest 104 263 269 1:CAS:528:DyaK1MXkvFagsbc%3D 10.1172/JCI6863 10430607
11. S Cascinu V Catalano C Aschele S Barni D Debernardis L Gallo R Bandelloni MP Staccioli AM Baldelli A Brenna A Valenti P Muretto G Catalano 2000 Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination Ann Oncol 11 1053 1056 1:STN:280:DC%2BD3cvoslOrtQ%3D%3D 10.1023/A:1008362511552 11038045
12. S Dong L Lester LF Johnson 2000 Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter J Cell Biochem 77 50 64 1:CAS:528:DC%2BD3cXhslygtLk%3D 10.1002/(SICI)1097-4644(20000401)77:1<50::AID-JCB6>3.0.CO;2-C 10679816 (Pubitemid 30126894)
13. Y Fukui T Oka S Nagayama PV Danenberg KD Danenberg M Fukushima 2008 Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis Int J Mol Med 22 709 716 1:CAS:528: DC%2BD1MXks1Srtg%3D%3D 19020767
14. MM Garrity LJ Burgart MR Mahoney HE Windschitl M Salim M Wiesenfeld JE Krook JC Michalak RM Goldberg MJ O'Connell AF Furth DJ Sargent LM Murphy E Hill DL Riehle CH Meyers TE Witzig 2004 Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study J Clin Oncol 22 1572 1582 1:CAS:528:DC%2BD2cXpsVWmuro%3D 10.1200/JCO.2004.10.042 15117979 (Pubitemid 41079794)
15. SR Hegde W Sun JP Lynch 2008 Systemic and targeted therapy for advanced colon cancer Expert Rev Gastroenterol Hepatol 2 135 149 1:CAS:528: DC%2BD1cXjtFOisbk%3D 10.1586/17474124.2.1.135 19072376
16. PJ Iaquinta JA Lees 2007 Life and death decisions by the E2F transcription factors Curr Opin Cell Biol 19 649 657 1:CAS:528: DC%2BD2sXhsVWisLvI 10.1016/j.ceb.2007.10.006 18032011 (Pubitemid 350216426)
17. Y Ishibiki M Kitajima K Sakamoto Y Tomiki S Sakamoto T Kamano 2003 Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer J Int Med Res 31 181 187 1:CAS:528:DC%2BD3sXlvV2ks74%3D 12870370
18. PG Johnston HJ Lenz CG Leichman KD Danenberg CJ Allegra PV Danenberg L Leichman 1995 Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors Cancer Res 55 1407 1412 1:CAS:528:DyaK2MXkslWis7c%3D 7882343
19. EG Konstantakou GE Voutsinas PK Karkoulis G Aravantinos LH Margaritis DJ Stravopodis 2009 Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses Int J Oncol 35 401 416 1:CAS:528:DC%2BD1MXpt12qur8%3D 19578756
20. Y Kubota T Miura M Moriyama S Noguchi J Matsuzaki S Takebayashi M Hosaka 1997 Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer Clin Cancer Res 3 973 976 1:STN:280:DyaK1M7htFShsA%3D%3D 9815773
21. BG Le Francois JA Maroun HC Birnboim 2007 Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F Br J Cancer 97 1242 1250 1:CAS:528:DC%2BD2sXht1aqtLjM 10.1038/sj.bjc.6604020 17923872 (Pubitemid 350035810)
22. HJ Lenz K Hayashi D Salonga KD Danenberg PV Danenberg R Metzger D Banerjee JR Bertino S Groshen LP Leichman CG Leichman 1998 p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival Clin Cancer Res 4 1243 1250 1:CAS:528:DyaK1cXjt1yiu70%3D 9607583
23. CC Lin CH Hsu CY Huang AL Cheng J Chen NJ Vogelzang YS Pu 2006 Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity Cancer 106 1269 1275 1:CAS:528:DC%2BD28XjtVCrsLw%3D 10.1002/cncr.21738 16470604 (Pubitemid 43363903)
24. HC Liu GG Chen AC Vlantis BC Leung MC Tong CA van Hasselt 2006 5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway Cancer J 12 482 493 1:CAS:528: DC%2BD2sXlvFyrtbk%3D 10.1097/00130404-200611000-00008 17207318
25. DB Longley DP Harkin PG Johnston 2003 5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 330 338 1:CAS:528: DC%2BD3sXjtlals70%3D 10.1038/nrc1074 12724731 (Pubitemid 37328853)
26. T Ma ZG Zhu YB Ji Y Zhang YY Yu BY Liu HR Yin YZ Lin 2004 Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine World J Gastroenterol 10 172 176 1:CAS:528:DC%2BD2cXhsVOku7o%3D 14716816
27. N Matsuhashi M Saio A Matsuo Y Sugiyama S Saji 2004 p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel Oncol Rep 12 357 361 1:CAS:528:DC%2BD2cXms1Kit7k%3D 15254702
28. M Matsumoto M Furihata Y Ohtsuki 2006 Posttranslational phosphorylation of mutant p53 protein in tumor development Med Mol Morphol 39 79 87 1:CAS:528:DC%2BD28XmsFOnurg%3D 10.1007/s00795-006-0320-0 16821145 (Pubitemid 44576787)
29. M Meyers MW Wagner HS Hwang TJ Kinsella DA Boothman 2001 Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses Cancer Res 61 5193 5201 1:CAS:528:DC%2BD3MXltVCjsrg%3D 11431359
30. Y Mizutani H Wada O Ogawa O Yoshida M Fukushima N Nonomura T Miki 2001 Prognostic significance of thymidylate synthase activity in bladder carcinoma Cancer 92 510 518 1:CAS:528:DC%2BD3MXmsVyjt7k%3D 10.1002/1097-0142(20010801)92: 3<510::AID-CNCR1349>3.0.CO;2-0 11505394 (Pubitemid 32735185)
31. Y Mizutani H Wada M Fukushima O Yoshida H Nakanishi YN Li T Miki 2004 Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma Cancer 100 723 731 1:CAS:528:DC%2BD2cXhvF2qtb8%3D 10.1002/cncr.11955 14770427 (Pubitemid 38176849)
32. K Okumura E Mekata H Shiomi H Naitoh H Abe Y Endo Y Kurumi T Tani 2008 Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer Cancer Chemother Pharmacol 61 587 594 1:CAS:528:DC%2BD1cXjsFajtg%3D%3D 10.1007/s00280-007-0511-y 17520254
33. JS Park S Young Yoon JM Kim YI Yeom YS Kim NS Kim 2004 Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray Cancer Lett 214 19 33 1:CAS:528: DC%2BD2cXntFWrsbc%3D 10.1016/j.canlet.2004.04.012 15331170 (Pubitemid 39141195)
34. GJ Peters HH Backus S Freemantle B van Triest G Codacci-Pisanelli CL van der Wilt K Smid J Lunec AH Calvert S Marsh HL McLeod E Bloemena S Meijer G Jansen CJ van Groeningen HM Pinedo 2002 Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism Biochim Biophys Acta 1587 194 205 1:CAS:528:DC%2BD38XkslKjur0%3D 12084461
35. RY Poon W Jiang H Toyoshima T Hunter 1996 Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage J Biol Chem 271 13283 13291 1:CAS:528:DyaK28XjtlGisbc%3D 10.1074/jbc.271.23.13706 8662825 (Pubitemid 26187983)
36. BM Putzer 2007 E2F1 death pathways as targets for cancer therapy J Cell Mol Med 11 239 251 1:STN:280:DC%2BD2s3nvVGqtQ%3D%3D 10.1111/j.1582-4934.2007. 00030.x 17488475 (Pubitemid 46693326)
37. PJ Real C Sanz O Gutierrez C Pipaon AM Zubiaga JL Fernandez-Luna 2006 Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells FEBS Lett 580 5905 5909 1:CAS:528:DC%2BD28XhtFWiu7bJ 10.1016/j.febslet.2006.08.088 17027756 (Pubitemid 44584291)
38. MF Reed WA Zagorski ES Knudsen 2007 RB activity alters checkpoint response and chemosensitivity in lung cancer lines J Surg Res 142 364 372 1:CAS:528:DC%2BD2sXhtVOgs7bF 10.1016/j.jss.2007.03.038 17640669 (Pubitemid 47418827)
39. T Riley E Sontag P Chen A Levine 2008 Transcriptional control of human p53-regulated genes Nat Rev Mol Cell Biol 9 402 412 1:CAS:528: DC%2BD1cXkvF2gtL8%3D 10.1038/nrm2395 18431400 (Pubitemid 351574202)
40. WP Roos B Kaina 2006 DNA damage-induced cell death by apoptosis Trends Mol Med 12 440 450 1:CAS:528:DC%2BD28Xosl2qtr8%3D 10.1016/j.molmed.2006.07.007 16899408 (Pubitemid 44291571)
41. YM Rustum 2004 Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9 2467 2473 1:CAS:528:DC%2BD2cXltl2nu7Y%3D 10.2741/1408 15353299
42. D Salonga KD Danenberg M Johnson R Metzger S Groshen DD Tsao-Wei HJ Lenz CG Leichman L Leichman RB Diasio PV Danenberg 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 1322 1327 1:CAS:528:DC%2BD3cXjtVOqt74%3D 10778957
43. R Soong N Shah M Salto-Tellez BC Tai RA Soo HC Han SS Ng WL Tan N Zeps D Joseph RB Diasio B Iacopetta 2008 Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy Ann Oncol 19 915 919 1:STN:280: DC%2BD1c3nvFWrtg%3D%3D 10.1093/annonc/mdm599 18245778 (Pubitemid 351627307)
44. R Sowers J Toguchida J Qin PA Meyers JH Healey A Huvos D Banerjee JR Bertino R Gorlick 2003 mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma Mol Cancer Ther 2 535 541 1:CAS:528:DC%2BD3sXlslWkt7g%3D 12813132
45. C Stevens NB La Thangue 2004 The emerging role of E2F-1 in the DNA damage response and checkpoint control DNA Repair (Amst) 3 1071 1079 1:CAS:528:DC%2BD2cXmtVeqt7c%3D 10.1016/j.dnarep.2004.03.034 (Pubitemid 38997950)
46. DJ Stravopodis LH Margaritis GE Voutsinas 2007 Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex Curr Med Chem 14 3122 3138 1:CAS:528: DC%2BD1cXhtlSrsLg%3D 10.2174/092986707782793925 18220746 (Pubitemid 350226961)
47. DJ Stravopodis PK Karkoulis EG Konstantakou S Melachroinou AD Lampidonis D Anastasiou S Kachrilas N Messini-Nikolaki IS Papassideri G Aravantinos LH Margaritis GE Voutsinas 2009 Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines Int J Oncol 34 137 160 1:CAS:528:DC%2BD1MXht1Cqsbg%3D 19082486
48. J Tozser P Bagossi G Zahuczky SI Specht E Majerova TD Copeland 2003 Effect of caspase cleavage-site phosphorylation on proteolysis Biochem J 372 137 143 10.1042/BJ20021901 12589706 (Pubitemid 36609615)
49. B Van Triest HM Pinedo G Giaccone GJ Peters 2000 Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors Ann Oncol 11 385 391 10.1023/A:1008351221345 10847455 (Pubitemid 30333539)
50. KH Vousden 2002 Activation of the p53 tumor suppressor protein Biochim Biophys Acta 1602 47 59 1:CAS:528:DC%2BD38XktVKgu7w%3D 11960694
51. KH Vousden 2006 Outcomes of p53 activation-spoilt for choice J Cell Sci 119 5015 5020 1:CAS:528:DC%2BD2sXhtFWmsb8%3D 10.1242/jcs.03293 17158908 (Pubitemid 46085181)
52. W Wang HL McLeod J Cassidy 2003 Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines Int J Cancer 104 504 511 1:CAS:528:DC%2BD3sXisVejt7c%3D 10.1002/ijc.10972 12584750 (Pubitemid 36323923)
53. W Wang HL McLeod J Cassidy ES Collie-Duguid 2007 Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks Cancer Chemother Pharmacol 59 839 845 1:CAS:528:DC%2BD2sXjt1WmtLY%3D 10.1007/s00280-006-0384-5 17119966 (Pubitemid 46440607)
54. CL Wei Q Wu VB Vega KP Chiu P Ng T Zhang A Shahab HC Yong Y Fu Z Weng J Liu XD Zhao JL Chew YL Lee VA Kuznetsov WK Sung LD Miller B Lim ET Liu Q Yu HH Ng Y Ruan 2006 A global map of p53 transcription-factor binding sites in the human genome Cell 124 207 219 1:CAS:528:DC%2BD28XntVGrsg%3D%3D 10.1016/j.cell.2005.10.043 16413492 (Pubitemid 43069320)
55. C Weiss DG Engehausen FS Krause T Papadopoulos J Dunst R Sauer C Rodel 2007 Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer Int J Radiat Oncol Biol Phys 68 1072 1080 1:CAS:528:DC%2BD2sXnslWjs70%3D 10.1016/j.ijrobp.2007.01.054 17467193 (Pubitemid 47048579)
56. JL Westra M Schaapveld H Hollema JP de Boer MM Kraak D de Jong A ter Elst NH Mulder CH Buys RM Hofstra JT Plukker 2005 Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients J Clin Oncol 23 5635 5643 1:CAS:528:DC%2BD2MXhtVersrzN 10.1200/JCO.2005.04.096 16110022
57. L Whitesell SL Lindquist 2005 HSP90 and the chaperoning of cancer Nat Rev Cancer 5 761 772 1:CAS:528:DC%2BD2MXhtVGjs7bF 10.1038/nrc1716 16175177 (Pubitemid 41400776)
58. MD Wyatt DM Wilson 3rd 2009 Participation of DNA repair in the response to 5-fluorouracil Cell Mol Life Sci 66 788 799 1:CAS:528:DC%2BD1MXisVOku7o%3D 10.1007/s00018-008-8557-5 18979208
59. KH Yeh CT Shun CL Chen JT Lin WJ Lee PH Lee YC Chen AL Cheng 1999 Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy Hepatogastroenterology 46 610 615 1:CAS:528:DyaK1MXitFyktr0%3D 10228869